For the moment, the Ministry of Health excludes mass vaccination against monkeypox, limiting it to risk categories. This is what is expected from a circulation of the ministry released yesterday evening, which reads: “At the moment, the mode of contagion and the speed of spread, as well as the effectiveness of non-pharmacological measures, exclude the need for a vaccination campaign. mass”. Read also The vaccin will be distributed first to the 4 Regions with the most cases: two thousand doses in Lombardy, 1.200 in Lazio, 600 in Emilia Romagna and 400 in Veneto. Furthermore, as requested, pending the next tranche of donation (currently scheduled for the second half of August), a portion of doses (multiples of 20 up to at 60 doses). A portion of the vaccine will remain stored at the Ministry of Health, for any emergencies, the circular states. THE CIRCULAR “Taking into account the current epidemic scenario and the limited availability of doses – the circular continues – the first high risk categories to which vaccination will initially be offered, as pre-exposure prophylaxis, are identified among: laboratory personnel with possible exposure directed at orthopoxvirus. gay, transgender, bisexual and other men who have sexual intercourse with men (MSM), who meet the following risk criteria: recent history (past 3 months) with multiple sexual partners; and / or participation in group sex; and / or participation in sexual encounters in local / club / cruising / saunas; and / or recent sexually transmitted infection (at least one episode in the past year); and / or habit of associating sexual acts with consumption of chemical drugs (Chemsex) “. These subjects at higher risk, explains the ministry in the circular,” could be identified among those who belong to the Prep-Hiv clinics of infectious disease centers and checkpoints, HIV centers and centers for the treatment of sexually transmitted diseases, also using high-risk behavior indicators similar to those used to assess eligibility for HIV pre-exposure prophylaxis, but applied regardless of whether or not HIV infection is present. The involvement of LGBTQIA + associations and those for the fight against HIV is considered important, in particular to promote correct information on the vaccination campaign. The vaccine offer strategy in favor of further target groups may be updated on the basis of epidemiological trends and the availability of doses. “” The currently available vaccine, Mva-bn (modified, non-replicating live Ankara vaccine virus, produced by Bavarian Nordic ), is a vaccine distributed in the United States under the name of Jynneos, and authorized by the FDA for the prevention of smallpox and monkeypox in adults at high risk of infection. “Mva-Bn is also authorized in Canada, with the trade name Imvamune, and in Europe, with the trade name Imvanex. According to Ema, between the two products (Jynneos and Imvanex) there are small differences in terms of production process and quality specifications between the various authorizations for placing on the market in different regions, due to differences in data sets, but which do not affect the final quality of the vaccine. More recently Ema has extended the indication for use of Imvanex (formerly indicated only for smallpox) also for monkeypox. SPALLANZANI From Monday 8 August the Spallanzani Institute starts the vaccination for monkeypox for the categories indicated in the Circular of the Ministry of Health. Those who fall within the categories listed can book by sending an email to: [email protected] For information on the eligible categories, you can read the Circular of the Ministry of Health here: https://bit.ly/monkeypoxvaxinmi.
Welcome! Log into your account
Recover your password
A password will be e-mailed to you.